Af­ter safe­ty re­view, EMA mir­rors FDA with up­dat­ed rec­om­men­da­tions for JAK in­hibitors

The EMA re­leased up­dat­ed rec­om­men­da­tions to­day for the use of JAK in­hibitors (JA­Ki) af­ter re­view­ing da­ta from sev­er­al clin­i­cal tri­als that showed in­creased in­ci­dents of is­sues in cer­tain pa­tients who have rheuma­toid arthri­tis and oth­er risk fac­tors.

The EMA not­ed ma­lig­nan­cy, ma­jor ad­verse car­dio­vas­cu­lar events (MACE), se­ri­ous in­fec­tions, ve­nous throm­boem­bolism (VTE) and mor­tal­i­ty in some pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER